Theranos, a Menlo Park company developing devices that enable healthcare professionals and pharmaceutical companies to track patients’ responses to drugs, has raised $28.5 million of a $30 million planned third round, according to a filing with the Securities and Exchange Commission cited by VentureWire (sub required).

ATA Ventures, Tako Ventures, Draper Fisher Jurvetson and Continental Properties Inc. were listed as investors in the Form D filing received by the SEC on Nov. 17.

The company raised more than $10 million in a second round in March, and an undisclosed amount in 2004, according to the report.

VentureBeat

VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
  • up-to-date information on the subjects of interest to you
  • our newsletters
  • gated thought-leader content and discounted access to our prized events, such as Transform
  • networking features, and more
Become a member